226997-95-1

Basic information

• Product Name: (R)-N-(2,6-dimethylbenzyl)-3-<(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl>-1,3-thiazolidine-4-carboxamide
• CAS NO: 226997-95-1
• Molecular Weight: 427.568
• Mol File: 226997-95-1.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (R)-N-(2,6-dimethylbenzyl)-3-<(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl>-1,3-thiazolidine-4-carboxamide(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-N-(2,6-dimethylbenzyl)-3-<(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl>-1,3-thiazolidine-4-carboxamide(226997-95-1)
• EPA Substance Registry System: (R)-N-(2,6-dimethylbenzyl)-3-<(2S,3S)-3-amino-2-hydroxy-4-phenylbutanoyl>-1,3-thiazolidine-4-carboxamide(226997-95-1)

Safety Data

• Hazardous Substances Data: 226997-95-1(Hazardous Substances Data)

Upstream product

• 1027226-32-9 4-(2,6-dimethyl-benzylcarbamoyl)-thiazolidine-3-carboxylic acid tert-butyl ester 
• 130403-21-3 2-(2,6-di-methylbenzyl)isoindoline-1,3-dione 
• 186538-17-0 (R)-N-(2,6-dimethylbenzyl)-1,3-thiazolidine-4-carboxamide 
• 62023-65-8 (2S,3S)-3-tert-butoxycarbonylamino-2-hydroxy-4-phenylbutanoic acid 
• 74788-82-2 (2,6-dimethylphenyl)methanamine 
• 62285-58-9 2,6-dimethylbenzyl alcohol 
• 14920-81-1 methyl 2,6-dimethylbenzoate 
• 5402-60-8 2,6-dimethylbenzyl chloride 
• 632-46-2 2,6-dimethylbenzoic acid 

Downstream Products

• 1055039-07-0 Acetic acid 3-{(1S,2S)-1-benzyl-3-[(R)-4-(2,6-dimethyl-benzylcarbamoyl)-thiazolidin-3-yl]-2-hydroxy-3-oxo-propylcarbamoyl}-2-methyl-phenyl ester 

Relevant articles and documents

Structure-activity relationship of small-sized HIV protease inhibitors containing allophenylnorstatine

We designed and synthesized a new class of peptidomimetic human immunodeficiency virus (HIV) protease inhibitors containing a unique unnatural amino acid, allophenylnorstatine [Apns; (2S,3S)-3-amino-2-hydroxy- 4-phenylbutyric acid], with a hydroxymethylcarbonyl (HMC) isostere as the active moiety. A systematic evaluation of structure - activity relationships for HIV protease inhibition, anti-HIV activities, and pharmacokinetic profiles has led to the delineation of a set of structural characteristics that appear to afford an orally available HIV protease inhibitor. Optimum structures, exemplified by 21f (JE-2147), incorporated 3-hydroxy-2- methylbenzoyl groups as the P2 ligand, (R)-5,5-dimethyl-1,3-thiazolidine-4- carbonyl (Dmt) residue at the P1' site, and 2-methylbenzylcarboxamide group as the P2' ligand. The present study demonstrated that JE-2147 has potent antiviral activities in vitro and exhibits good oral bioavailability and plasma pharmacokinetic profiles in two species of laboratory animals.